Pancreatic Cancer


Each year, more and more Americans will hear the words, “You have pancreatic cancer.” In 2021, an estimated 60,430 will receive this diagnosis (31,950 men and 28,480 women), 70% will die in the first year, the 5 year survival rate is only 9%. Pancreatic Cancer is a formidable disease, recently rising to the 3rd leading cause of cancer death in the United States. It is expected to become the 2nd by 2022. There are no early detection tools. In spite of the number of people affected by this disease and a staggering mortality rate which is higher than all other major cancers, research funding is shockingly inadequate and has remained largely unchanged for the past 40 years. Pancreatic Cancer initiatives receive less than 3% of the National Cancer Institute’s (NCI) research budget.

Funding from organizations like ours is critical for key progressive research and treatment initiatives.

Our mission is to both raise money for pancreatic cancer research and patient programs, as well as make people aware of the funding needs.

Much of our funding to-date has been directed towards, funding conceptual, out-of-the-box translational research at Jefferson University Sidney Kimmel Cancer Center – an NCI-designated facility. This is the leading pancreatic cancer research and treatment center in our region and where Amy received her treatment. Other funding has been directed to patient programs and patient support at both Jefferson most recently to our newest partner, St. Luke’s Hospital. St. Luke’s Cancer Center at St. Lukes Quakertown Campus, located in our direct community.